REGENXBIO Inc.
REGENXBIO Inc. (Nasdaq: RGNX) is a clinical-stage biotechnology company developing gene therapies based on its NAV® Technology Platform, a proprietary collection of adeno-associated virus vectors designed to deliver functional genes to cells. Its internal pipeline focuses on retinal, neuromuscular and… From the company’s description.
Over the twelve months to Sep 30, 2026, REGENXBIO Inc. reported revenue of $153.91M, down 4.6% from a year earlier, and a net loss of $175.23M. Its operating margin was −95.7%, and operations used $152.10M in cash. In fiscal 2025, it reported revenue of $170.44M, up 104.5% from fiscal 2024, and a net loss of $193.88M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What REGENXBIO Inc. does
In the company’s own words
REGENXBIO Inc. (Nasdaq: RGNX) is a clinical-stage biotechnology company developing gene therapies based on its NAV® Technology Platform, a proprietary collection of adeno-associated virus vectors designed to deliver functional genes to cells. Its internal pipeline focuses on retinal, neuromuscular and neurodegenerative diseases, with candidates for wet age-related macular degeneration and diabetic retinopathy, Duchenne muscular dystrophy, and MPS I and MPS II. The company also licenses NAV vectors to biopharmaceutical partners, whose programs include Novartis’s Zolgensma and Itvisma for spinal muscular atrophy. REGENXBIO operates research, development and manufacturing capabilities, including its Rockville-based GMP facility and NAVXpress® production platform. Its lead programs are developed through collaborations with AbbVie and Nippon Shinyaku. The NAV platform has supported two FDA-approved partner therapies and investigational programs across multiple disease areas. For the fiscal year ended December 31, 2025, REGENXBIO reported total revenue of $[not stated in supplied text]. Its website is www.regenxbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- ROCKVILLE, MD
- Fiscal year end
- December
- CIK
- 1590877
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns REGENXBIO Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · REGENXBIO Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do REGENXBIO Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of REGENXBIO Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in REGENXBIO Inc.'s last four quarterly filings that the numbers alone won't show?”